<DOC>
	<DOCNO>NCT01381601</DOCNO>
	<brief_summary>Information prevalence advanced/metastatic renal cell carcinoma symptom burden limit commercially insured adult patient . Additionally , limited information exist economic burden adverse event associate treatment advanced/metastatic renal cell carcinoma . An objective current study estimate incidence , prevalence , symptom burden associate advanced/metastatic RCC US `` real-world '' setting . Another objective quantify economic burden severe adverse event agent use management first line advanced/metastatic RCC ( sunitinib , sorafenib , bevacizumab , pazopanib ) . This study employ retrospective cohort design . Analyses health insurance claim data large commercially insured population employ current study . Study subject consist person , age â‰¥18 year , evidence advance RCC January 1 , 2000 December 31 , 2009 ; person identify base part case-ascertainment algorithm . Analyses direct estimate annual rate incidence prevalence advanced/metastatic RCC , well symptom burden cost common severe adverse event associated treatment use management advanced/metastatic RCC ( sunitinib , sorafenib , bevacizumab , pazopanib ) .</brief_summary>
	<brief_title>Incidence , Prevalence , Symptom Burden Associated With Advanced Renal Cell Carcinoma Commercially Insured Population ( Pharmetrics )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>two medical encounter diagnosis kidney cancer ( ICD9CM 189.0 ) malignant neoplasm renal pelvis ( 189.1 ) , two medical encounter diagnosis distant secondary malignant neoplasm ( ICD9CM 197.XX199.0 , exclude 198.0 [ kidney metastasis ] ) different day &lt; 120 day apart ( date early encounter designate `` index date '' ) . evidence receipt chemotherapeutic agent indicate used treatment advance TCC , evidence cystoscopy , biopsy bladder , radical cystectomy evidence primary cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>retrospective database analysis</keyword>
	<keyword>economic burden</keyword>
</DOC>